PT2573166T - Métodos para preparar células-t para terapia celular - Google Patents

Métodos para preparar células-t para terapia celular

Info

Publication number
PT2573166T
PT2573166T PT121777320T PT12177732T PT2573166T PT 2573166 T PT2573166 T PT 2573166T PT 121777320 T PT121777320 T PT 121777320T PT 12177732 T PT12177732 T PT 12177732T PT 2573166 T PT2573166 T PT 2573166T
Authority
PT
Portugal
Prior art keywords
cells
preparing
methods
cell therapy
therapy
Prior art date
Application number
PT121777320T
Other languages
English (en)
Inventor
Har-Noy Michael
Original Assignee
Immunovative Therapies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunovative Therapies Ltd filed Critical Immunovative Therapies Ltd
Publication of PT2573166T publication Critical patent/PT2573166T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2531/00—Microcarriers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/30—Synthetic polymers
    • C12N2533/40—Polyhydroxyacids, e.g. polymers of glycolic or lactic acid (PGA, PLA, PLGA); Bioresorbable polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
PT121777320T 2004-02-26 2005-02-24 Métodos para preparar células-t para terapia celular PT2573166T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US54796604P 2004-02-26 2004-02-26

Publications (1)

Publication Number Publication Date
PT2573166T true PT2573166T (pt) 2016-07-07

Family

ID=34910966

Family Applications (1)

Application Number Title Priority Date Filing Date
PT121777320T PT2573166T (pt) 2004-02-26 2005-02-24 Métodos para preparar células-t para terapia celular

Country Status (14)

Country Link
US (6) US7678572B2 (pt)
EP (3) EP2573166B1 (pt)
JP (5) JP2007525225A (pt)
CA (1) CA2555714C (pt)
CY (1) CY1117750T1 (pt)
DK (1) DK2573166T3 (pt)
ES (1) ES2586295T3 (pt)
HU (1) HUE028467T2 (pt)
IL (1) IL177404A (pt)
LT (1) LT2573166T (pt)
PL (1) PL2573166T3 (pt)
PT (1) PT2573166T (pt)
SI (1) SI2573166T1 (pt)
WO (1) WO2005081982A2 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7435592B2 (en) 2003-05-13 2008-10-14 Immunovative Therapies, Ltd. Compositions for allogeneic cell therapy
US7592431B2 (en) * 2004-02-26 2009-09-22 Immunovative Therapies, Ltd. Biodegradable T-cell Activation device
JP2007525225A (ja) 2004-02-26 2007-09-06 イミュノバティブ セラピーズ， リミテッド 細胞治療のためのｔ細胞を調製するための方法
CA2530514C (en) * 2004-03-01 2017-01-31 Immunovative Therapies, Ltd. Cell therapy formulation method and composition
US9320794B2 (en) 2006-11-13 2016-04-26 Immunovative Therapies, Ltd. Ablative immunotherapy
US7972594B2 (en) 2006-11-13 2011-07-05 Immunovative Therapies Ltd. Ablative immunotherapy
US10155038B2 (en) 2007-02-02 2018-12-18 Yale University Cells prepared by transient transfection and methods of use thereof
WO2008097926A2 (en) * 2007-02-02 2008-08-14 Yale University Transient transfection with rna
US9249423B2 (en) 2007-02-02 2016-02-02 Yale University Method of de-differentiating and re-differentiating somatic cells using RNA
US9695397B2 (en) 2008-10-01 2017-07-04 Immunovative Therapies Ltd. Th1 vaccination priming for active immunotherapy
US20120128656A1 (en) 2008-05-02 2012-05-24 Immunovative Therapies, Ltd. Vaccine compositions and methods
KR101900807B1 (ko) * 2010-08-20 2018-11-08 이뮤노베이티브 테라피스, 엘티디. 헬퍼 t1 특성들 및 세포용해 특성들을 발현하는 세포들
WO2012151279A2 (en) 2011-05-03 2012-11-08 Michael Har-Noy Induction of il-12 using immunotherapy
AU2012250794B2 (en) 2011-05-03 2015-11-05 Immunovative Therapies, Ltd. Methods for handling biological drugs containing living cells
CN105392876B (zh) * 2013-06-24 2019-07-23 威尔逊沃夫制造公司 用于透气性细胞培养过程的封闭系统装置和方法
CN103525763A (zh) * 2013-09-28 2014-01-22 青岛麦迪赛斯生物科技有限公司 一种高效cik细胞的培养方法
BR112016015736B1 (pt) 2014-01-08 2022-01-04 Immunovative Therapies, Ltd. Uso de um aloantígeno, uma molécula que interage com receptor de superfície cd40 e citocinas tipo i; e pelo menos um ou mais antígenos de hiv, kit, composição e composição de avi
MA45488A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés, kits et appareil de culture de cellules
EP3390454A4 (en) * 2015-12-17 2019-08-28 University of Maryland, Baltimore County RECOMBINANT POLYPEPTIDE BISPECIFIC FOR COORDINATED ACTIVATION OF TUMOR REAGENT T CELLS AND NEUTRALIZATION OF IMMUNE REMOVAL
CA3016925A1 (en) * 2016-03-17 2017-09-21 Xiaohua Wang Selection and cloning of t lymphocytes in a microfluidic device
EP3452290B1 (en) 2016-05-05 2021-07-14 Southwest Research Institute Three-dimensional bioreactor for cell expansion and related applications
US10294454B2 (en) 2016-08-24 2019-05-21 General Electric Company Methods and kits for cell activation
US11149244B2 (en) 2018-04-04 2021-10-19 Southwest Research Institute Three-dimensional bioreactor for T-cell activation and expansion for immunotherapy
WO2020068840A1 (en) 2018-09-24 2020-04-02 Southwest Research Institute Three-dimensional bioreactors

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2439003A1 (fr) 1978-10-20 1980-05-16 Anvar Nouvelles pieces d'osteosynthese, leur preparation et leur application
US4279248A (en) * 1979-07-20 1981-07-21 Shlomo Gabbay Sternum closure device and procedure for using same
US5766920A (en) 1982-08-11 1998-06-16 Cellcor, Inc. Ex vivo activation of immune cells
AU7873187A (en) 1986-08-08 1988-02-24 University Of Minnesota Method of culturing leukocytes
PT89121A (pt) 1987-12-04 1989-12-29 Du Pont Processo para a preparacao de interleuquina-2 imobilizada e interleuquina-2 contendo uma extensao no terminal-carboxilo com actividade de interleuquina-2 natural
US6534055B1 (en) * 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
WO1993019767A1 (en) * 1992-04-07 1993-10-14 The Regents Of The University Of Michigan Cd28 pathway immunoregulation
IL92382A (en) * 1988-11-23 1994-12-29 Univ Michigan Use of a ligand specific for CD28 in the manufacture of medicament
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6905680B2 (en) * 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US5126132A (en) 1989-08-21 1992-06-30 The United States Of America As Represented By The Department Of Health And Human Services Tumor infiltrating lymphocytes as a treatment modality for human cancer
US5728388A (en) 1989-10-03 1998-03-17 Terman; David S. Method of cancer treatment
CA2065658A1 (en) * 1991-04-19 1992-10-20 Tse-Wen Chang Conjugates of liposomes or microbeads and antibodies specific for t lymphocytes and their use in vivo immune modulators
JP3355666B2 (ja) * 1992-10-22 2002-12-09 ソニー株式会社 変調回路
AU5729294A (en) 1992-11-25 1994-06-22 Tanox Biosystems, Inc. Conjugates and constructs including anti-cd28 and anti-cd3 binding molecules
EP0700430B1 (en) * 1993-06-04 2005-04-20 The United States of America as Represented by the Secretary of the Navy Methods for selectively stimulating proliferation of t cells
WO1995004817A1 (en) 1993-08-06 1995-02-16 Cytel Corporation Methods for ex vivo therapy using peptide-loaded antigen presenting cells for the activation of ctl
IL107483A0 (en) 1993-11-03 1994-02-27 Yeda Res & Dev Bone marrow transplantation
CA2191586A1 (en) * 1994-06-03 1995-12-14 Carl H. June Methods for selectively stimulating proliferation of t cells
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
DE69628154T2 (de) 1995-03-08 2004-03-18 The Scripps Research Institute, La Jolla Antigen präsentierendes system und aktivierung von t-zellen
DE19545257A1 (de) * 1995-11-24 1997-06-19 Schering Ag Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln
DE69739951D1 (de) 1996-03-04 2010-09-16 Calyx Bio Ventures Inc Modifizierte schnellvermehrungsmethode ('modified-rem') zur in vitro vermehrung von t-lymphozyten
ATE347588T1 (de) 1996-05-23 2006-12-15 Scripps Research Inst Systeme zur präsentation von mhc-antigenen der klasse ii und verfahren zur aktivierung von cd4?+-t-lymphozyten
WO1998024483A2 (en) * 1996-12-03 1998-06-11 Osteobiologics, Inc. Biodegradable polymeric film
CA2278847A1 (en) 1997-01-31 1998-08-06 Hemosol Inc. Method for the production of selected lymphocytes
JP4132089B2 (ja) * 1997-05-30 2008-08-13 オステオバイオロジックス，インコーポレイテッド 繊維強化多孔性生体分解性移植デバイス
EP1030674A1 (en) 1997-11-10 2000-08-30 Arch Development Corporation METHODS FOR TREATMENT OF TUMORS AND TUMOR CELLS USING $i(EX VIVO) ACTIVATED T CELLS
JP2003517810A (ja) * 1999-01-29 2003-06-03 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 抗−ｃｃｒ１抗体およびその使用方法
JP2001054563A (ja) * 1999-07-12 2001-02-27 Isotis Bv 縫合糸
AU2001233277B2 (en) * 2000-02-03 2004-06-03 Millennium Pharmaceuticals, Inc. Humanized anti-ccr2 antibodies and methods of use therefor
WO2001058916A2 (en) * 2000-02-09 2001-08-16 Human Genome Sciences, Inc. Antibodies to ccr5
US20030119185A1 (en) * 2000-02-24 2003-06-26 Xcyte Therapies, Inc. Activation and expansion of cells
ATE373078T1 (de) 2000-02-24 2007-09-15 Xcyte Therapies Inc Gleichzeitige stimulation und konzentration von zellen
US6867041B2 (en) * 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
WO2002017935A2 (en) 2000-08-31 2002-03-07 Emory University A method of transplantation using chemotherapy-treated allogeneic cells that enhance immune responses without graft versus host disease
US6626950B2 (en) * 2001-06-28 2003-09-30 Ethicon, Inc. Composite scaffold with post anchor for the repair and regeneration of tissue
AU2002342299A1 (en) 2001-10-31 2003-05-12 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Generation of use of tc1 and tc2 cells
AU2002351277A1 (en) * 2001-12-06 2003-07-09 Georgia Tech Research Corporation Biodegradable, porous structures useful for growing living tissue, and methods of manufacture
US7638325B2 (en) * 2002-01-03 2009-12-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform
US20030175272A1 (en) * 2002-03-07 2003-09-18 Medcell Biologics, Inc. Re-activated T-cells for adoptive immunotherapy
DE10230223A1 (de) * 2002-07-04 2004-01-22 Tegenero Ag Mikropartikel mit CD28-spezifischen monoklonalen Antikörpern
WO2004006951A1 (en) 2002-07-12 2004-01-22 The Johns Hopkins University Reagents and methods for engaging unique clonotypic lymphocyte receptors
US7402431B2 (en) * 2004-03-01 2008-07-22 Immunovative Therapies, Ltd. T-cell therapy formulation
US7435592B2 (en) * 2003-05-13 2008-10-14 Immunovative Therapies, Ltd. Compositions for allogeneic cell therapy
US7371228B2 (en) * 2003-09-19 2008-05-13 Medtronic Vascular, Inc. Delivery of therapeutics to treat aneurysms
US7592431B2 (en) * 2004-02-26 2009-09-22 Immunovative Therapies, Ltd. Biodegradable T-cell Activation device
JP2007525225A (ja) 2004-02-26 2007-09-06 イミュノバティブ セラピーズ， リミテッド 細胞治療のためのｔ細胞を調製するための方法
US7446099B2 (en) * 2004-02-27 2008-11-04 Nitto Denko Corporation Compositions and methods for biodegradable polymer-peptide mediated transfection
CA2530514C (en) 2004-03-01 2017-01-31 Immunovative Therapies, Ltd. Cell therapy formulation method and composition
WO2005089127A2 (en) * 2004-03-05 2005-09-29 The Trustees Of Columbia University In The City Of New York Polymer-ceramic-hydrogel composite scaffold for osteochondral repair

Also Published As

Publication number Publication date
EP2573166B1 (en) 2016-05-11
JP2014042529A (ja) 2014-03-13
US7956164B2 (en) 2011-06-07
JP2017093468A (ja) 2017-06-01
US8313944B2 (en) 2012-11-20
JP2011072319A (ja) 2011-04-14
US7678572B2 (en) 2010-03-16
US20110281357A1 (en) 2011-11-17
WO2005081982A3 (en) 2007-01-25
US8883974B2 (en) 2014-11-11
US8071374B2 (en) 2011-12-06
JP2015129184A (ja) 2015-07-16
SI2573166T1 (sl) 2016-09-30
HUE028467T2 (en) 2016-12-28
US20050191291A1 (en) 2005-09-01
DK2573166T3 (da) 2016-07-04
US20110177596A1 (en) 2011-07-21
US9593308B2 (en) 2017-03-14
WO2005081982A2 (en) 2005-09-09
US20100113753A1 (en) 2010-05-06
EP1776583A4 (en) 2009-04-29
US20150024489A1 (en) 2015-01-22
CA2555714A1 (en) 2005-09-09
CA2555714C (en) 2013-12-03
JP2007525225A (ja) 2007-09-06
EP3067415A1 (en) 2016-09-14
IL177404A (en) 2016-12-29
ES2586295T3 (es) 2016-10-13
IL177404A0 (en) 2007-07-04
JP6031021B2 (ja) 2016-11-24
EP2573166A2 (en) 2013-03-27
PL2573166T3 (pl) 2016-11-30
US20100255043A1 (en) 2010-10-07
EP2573166A3 (en) 2013-05-29
LT2573166T (lt) 2016-09-26
EP1776583A2 (en) 2007-04-25
CY1117750T1 (el) 2017-05-17

Similar Documents

Publication Publication Date Title
LT2573166T (lt) T ląstelių paruošimo būdas ląstelių terapijai
GB2411178A8 (en) Apparatus for culturing cells
EP1815244A4 (en) DEVICE FOR CULTURING CELLS
PT2266544T (pt) Método para introdução de substâncias terapêuticas em células
EP1729798A4 (en) THERAPY USING ANTIGEN-SPECIFIC T LYMPHOCYTES
GB2418305B (en) Charger
IL183091A0 (en) Method for preparing n-phenylpyrazole-1-carboxyamides
EP1769066A4 (en) MODIFIED ANTIGEN PRESENTATION CELLS
TWI316307B (en) Case for batteries and preparation method thereof
IL184262A (en) A method for culturing cells in culture
ZAA200500371S (en) Battery
GB2404665B (en) Cell culture
EP1820847A4 (en) COMPOSITION FOR COOLANT STORAGE OF CELLS
EP1820852A4 (en) HUMAN SERUM FOR CELL CULTURE
ZA200703293B (en) Cell bandage
ZA200506732B (en) Cell culture
EP1776182A4 (en) APPARATUS FOR ENCAPSULATING CELLS
EP1807508A4 (en) METHODS FOR PREPARING CELLS AND VIRUSES
ZA200704058B (en) Methods for producing mammalian cells
EP1725652A4 (en) CULTURE PROCESSES OF CRYPTOSPORIDIUM
GB2418056B (en) Battery
GB2409897B (en) Spectroscopy cell
GB0401766D0 (en) Phoretic cell
EP1871872A4 (en) METHOD FOR ACTIVATING CD8 T LYMPHOCYTES
GB0403172D0 (en) Rechargeable cell system